Imperial College spin-out company NK:IO has completed a seed round to a total of £5.9 ($7.8) million. The round included additional funding from UK Innovation Science and Seed Fund (UKI2S), managed by Future Planet Capital, Cambridge Angels and Cancer Research Horizons. The company says the funds will be used to progress NK cell therapeutics, initially […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!